All Outputs (20)

Connexin 43 is an independent predictor of patient outcome in breast cancer patients (2018)
Journal Article
Chasampalioti, M., Green, A. R., Ellis, I. O., Rakha, E. A., Jackson, A. M., Spendlove, I., & Ramage, J. M. (2019). Connexin 43 is an independent predictor of patient outcome in breast cancer patients. Breast Cancer Research and Treatment, 174(1), 93-102. https://doi.org/10.1007/s10549-018-5063-9

Purpose Gap junctions are specialized membrane structures that form channels between adjacent cells allowing cell communication. Gap junctions and specifically Connexin 43 (Cx43) are down-regulated in cancer; however, there are contrasting reports... Read More about Connexin 43 is an independent predictor of patient outcome in breast cancer patients.

Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ (2018)
Journal Article
Toss, M. S., Miligy, I. M., Gorringe, K. L., McCaffrey, L., Alkawaz, A., Abidi, A., …Rakha, E. A. (2019). Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ. Modern Pathology, 32, 639-649. https://doi.org/10.1038/s41379-018-0180-x

© 2018, United States & Canadian Academy of Pathology. Legumain is a proteolytic enzyme that plays a role in the regulation of cell proliferation in invasive breast cancer. Studies evaluating its role in ductal carcinoma in situ (DCIS) are lacking.... Read More about Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ.

Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS) (2018)
Journal Article
Toss, M. S., Miligy, I. M., Gorringe, K. L., Alkawaz, A., Khout, H., Ellis, I. O., …Rakha, E. (2018). Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS). British Journal of Cancer, 119(12), 1518-1526. https://doi.org/10.1038/s41416-018-0337-x

© 2018, Cancer Research UK. Background: Extracellular matrix (ECM) plays a crucial role in tumour behaviour. Prolyl-4-hydroxlase-A2 (P4HA2) is a key enzyme in ECM remodelling. This study aims to evaluate the prognostic significance of P4HA2 in breast... Read More about Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).

Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update (2018)
Journal Article
Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M., …Dowsett, M. (2018). Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update. Archives of Pathology and Laboratory Medicine, 142(11), 1364-1382. https://doi.org/10.5858/arpa.2018-0902-sa

© 2018 College of American Pathologists Published by the College of American Pathologists Allen Press, Inc. Purpose. - To update key recommendations of the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) human epid... Read More about Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update.

Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition (2018)
Journal Article
Chen, X., Low, K. H., Alexander, A., Jiang, Y., Karakas, C., Hess, K. R., …Keyomarsi, K. (2018). Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition. Clinical Cancer Research, https://doi.org/10.1158/1078-0432.ccr-18-1446

Purpose: Poor prognosis in triple-negative breast cancer (TNBC) is due to an aggressive phenotype and lack of biomarker-driven targeted therapies. Overexpression of cyclin E and phosphorylated-CDK2 are correlated with poor survival in TNBC patients,... Read More about Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition.

An end-to-end deep learning histochemical scoring system for breast cancer TMA (2018)
Journal Article
Liu, J., Xu, B., Zheng, C., Gong, Y., Garibaldi, J., Soria, D., …Qiu, G. (2019). An end-to-end deep learning histochemical scoring system for breast cancer TMA. IEEE Transactions on Medical Imaging, 38(2), 617-628. https://doi.org/10.1109/TMI.2018.2868333

One of the methods for stratifying different molecular classes of breast cancer is the Nottingham prognostic index plus, which uses breast cancer relevant biomarkers to stain tumor tissues prepared on tissue microarray (TMA). To determine the molecul... Read More about An end-to-end deep learning histochemical scoring system for breast cancer TMA.

Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors (2018)
Journal Article
Pareja, F., Brandes, A. H., Basili, T., Selenica, P., Geyer, F. C., Fan, D., …Reis-Filho, J. S. (2018). Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. Nature Communications, 9, Article 3533. https://doi.org/10.1038/s41467-018-05886-y

Granular cell tumors (GCTs) are rare tumors that can arise in multiple anatomical locations, and are characterized by abundant intracytoplasmic granules. The genetic drivers of GCTs are currently unknown. Here, we apply whole-exome sequencing and tar... Read More about Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors.

Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells (2018)
Journal Article
Hutcheson, I. R., Knowlden, J. M., Hiscox, S. E., Barrow, D., Gee, J. M. W., Robertson, J. F., …Nicholson, R. I. (2018). Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Research, 20, Article 98 (2018). https://doi.org/10.1186/s13058-018-0999-6

© 2018 The Author(s). After the publication of this work [1], an error was noticed in Fig. 2b and Fig. 4b as well as Fig. 4b. and Fig. 5d. Images of the ERK1/2 blots were accidentally duplicated. In Fig. 5a. and Fig. 5c., the last lane for p-ERK1/2 w... Read More about Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.

The spectrum of triple-negative breast disease: high- and low-grade lesions (2018)
Journal Article
Geyer, F. C., Pareja, F., Weigelt, B., Rakha, E., Ellis, I. O., Schnitt, S. J., & Reis-Filho, J. S. (2018). The spectrum of triple-negative breast disease: high- and low-grade lesions. American Journal of Pathology, 187(10), 2139-2151. https://doi.org/10.1016/j.ajpath.2017.03.016

Triple-negative breast cancer is viewed clinically as an aggressive subgroup of breast cancer. In fact, most triple-negative breast cancers are poor-prognosis tumors with a complex genomic landscape. However, triple-negative disease is vastly heterog... Read More about The spectrum of triple-negative breast disease: high- and low-grade lesions.

Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update (2018)
Journal Article
Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M., …Dowsett, M. (2018). Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Journal of Clinical Oncology, 36(20), 2105-2122. https://doi.org/10.1200/jco.2018.77.8738

Purpose: To update key recommendations of the American Society of Clinical Oncology / College of American Pathologists human epidermal growth factor receptor 2 (HER2) testing in breast cancer gudeline. Methods: Based on the signals approach, an Exp... Read More about Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update.

Treatment strategies and survival outcomes in older women with breast cancer: a comparative study between the FOCUS cohort and Nottingham cohort (2018)
Journal Article
Schuil, H., Derks, M., Liefers, G.-J., Portielje, J., van de Velde, C., Syed, B., …Bastiaannet, E. (in press). Treatment strategies and survival outcomes in older women with breast cancer: a comparative study between the FOCUS cohort and Nottingham cohort. Journal of Geriatric Oncology, https://doi.org/10.1016/j.jgo.2018.05.004

Objective: Clinical trials investigating breast cancer treatment often exclude or misrepresent older adults. This study compares treatment patterns and survival of older women diagnosed with breast cancer between a Dutch and a British observational c... Read More about Treatment strategies and survival outcomes in older women with breast cancer: a comparative study between the FOCUS cohort and Nottingham cohort.

Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas (2018)
Journal Article
Geyer, F. C., Li, A., Papanastasiou, A. D., Smith, A., Selenica, P., Burke, K. A., …Reis-Filho, J. S. (2018). Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. Nature Communications, 9, Article 1816. https://doi.org/10.1038/s41467-018-04128-5

Adenomyoepithelioma of the breast is a rare tumor characterized by epithelial-myoepithelial differentiation, of which a subset will progress to invasive or metastatic cancer. We sought to define the genomic landscape of adenomyoepitheliomas. Massivel... Read More about Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas.

Low expression of G protein-coupled oestrogen receptor 1 (GPER) is associated with adverse survival of breast cancer patients (2018)
Journal Article
Martin, S. G., Lebot, M. N., Sukkarn, B., Ball, G., Green, A. R., Rakha, E. A., …Storr, S. J. (2018). Low expression of G protein-coupled oestrogen receptor 1 (GPER) is associated with adverse survival of breast cancer patients. Oncotarget, 9(40), 25946-25956. https://doi.org/10.18632/oncotarget.25408

G protein-coupled oestrogen receptor 1 (GPER), also called G protein-coupled receptor 30 (GPR30), is attracting considerable attention for its potential role in breast cancer development and progression. Activation by oestrogen (17β-oestradiol; E2) i... Read More about Low expression of G protein-coupled oestrogen receptor 1 (GPER) is associated with adverse survival of breast cancer patients.

Diagnostic concordance of reporting lymphovascular invasion in breast cancer (2018)
Journal Article
Rakha, E. A., Abbas, A., Pinto Ahumada, P., ElSayed, M. E., Colman, D., Pinder, S. E., & Ellis, I. O. (2018). Diagnostic concordance of reporting lymphovascular invasion in breast cancer. Journal of Clinical Pathology, 71(9), 802-805. https://doi.org/10.1136/jclinpath-2017-204981

Aims: This study aims to assess the diagnostic agreement of lymphovascular invasion (LVI) in invasive breast cancer (BC). Methods: Data on LVI were collected from the UK National Health Service Breast Screening Programme pathology external quality... Read More about Diagnostic concordance of reporting lymphovascular invasion in breast cancer.

Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast (2018)
Journal Article
Toss, M. S., Miligy, I., Al-Kawaz, A., Alsleem, M., Khout, H., Rida, P. C., …Rakha, E. (in press). Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. Modern Pathology, https://doi.org/10.1038/s41379-018-0040-8

Tumor-infiltrating lymphocytes (TILs) provide prognostic value in invasive breast cancer and guidelines for their assessment have been published. This study aims to evaluate: (a) methods of TILs assessment, and (b) their prognostic significance in br... Read More about Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast.

Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort (2018)
Journal Article
Mukherjee, A., Russell, R., Chin, S.-F., Liu, B., Rueda, O., Ali, H., …Provenzano, E. (2018). Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort. npj Breast Cancer, 4(1), Article 5. https://doi.org/10.1038/s41523-018-0056-8

The integration of genomic and transcriptomic profiles of 2000 breast tumours from the METABRIC [Molecular Taxonomy of Breast Cancer International Consortium] cohort revealed ten subtypes, termed integrative clusters (IntClust/s), characterised by di... Read More about Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort.

Immune infiltration in invasive lobular breast cancer (2018)
Journal Article
Desmedt, C., Salgado, R., Fornili, M., Pruneri, G., Gert Van den Eynden, G., Zoppoli, G., …Sotiriou, C. (2018). Immune infiltration in invasive lobular breast cancer. JNCI: Journal of the National Cancer Institute, 110(7), 768–776. https://doi.org/10.1093/jnci/djx268

Background: Invasive lobular breast cancer (ILC) is the second most common histological subtype of breast cancer after invasive ductal cancer (IDC). Here, we aimed at evaluating the prevalence, levels and composition of tumor infiltrating lymphocytes... Read More about Immune infiltration in invasive lobular breast cancer.

First international TNBC conference meeting report (2018)
Journal Article
Rida, P., Ogden, A., Ellis, I. O., Varga, Z., Wolff, A. C., Traina, T. A., …Aneja, R. (2018). First international TNBC conference meeting report. Breast Cancer Research and Treatment, 169(3), 407-412. https://doi.org/10.1007/s10549-018-4692-3

Recently, Georgia State University’s Centennial Hall was the premier location for the 2017 International Conference on Triple Negative Breast Cancer (TNBC): Illuminating Actionable Biology, which was held from Sept. 18 to 20, 2017, in Atlanta, USA. T... Read More about First international TNBC conference meeting report.

BQ323636.1, a novel splice variant to NCOR2, as a predictor for tamoxifen resistant breast cancer (2018)
Journal Article
Gong, C., Man, E. P., Tsoi, H., Lee, T. K., Paul, L., Mak, S.-T., …Khoo, U.-S. (2018). BQ323636.1, a novel splice variant to NCOR2, as a predictor for tamoxifen resistant breast cancer. Clinical Cancer Research, 24(15), 3681-3691. https://doi.org/10.1158/1078-0432.CCR-17-2259

Purpose: Adjuvant tamoxifen treatment revolutionized the management of estrogen receptor (ER) positive breast cancers to prevent cancer recurrence; however drug resistance compromises its clinical efficacy. The mechanisms underlying tamoxifen resista... Read More about BQ323636.1, a novel splice variant to NCOR2, as a predictor for tamoxifen resistant breast cancer.

High nuclear MSK1 is associated with longer survival in breast cancer patients (2018)
Journal Article
Pu, X., Storr, S. J., Ahmad, N., Rakha, E., Green, A. R., Ellis, I. O., & Martin, S. G. (2018). High nuclear MSK1 is associated with longer survival in breast cancer patients. Journal of Cancer Research and Clinical Oncology, 144(3), https://doi.org/10.1007/s00432-018-2579-7

Purpose: Mitogen- and stress- activated kinases (MSKs) are important substrates of the mitogen-activated protein kinase (MAPK)-activated protein kinase family. MSK1 and MSK2 are both nuclear serine/threonine protein kinases, with MSK1 being suggested... Read More about High nuclear MSK1 is associated with longer survival in breast cancer patients.